Recent discussions on X about Danaher Corporation (DHR) have focused on the stock's performance amidst a cooling trend following a sharp run-up. Many users are pointing to specific price zones as potential support levels, indicating a cautious watch on the stock’s short-term movements. The conversation also reflects a mix of technical analysis and broader curiosity about the company’s next steps.
Additionally, there’s lingering admiration for Danaher’s long-term business model, with some highlighting the impact of the Danaher Business System as a driver of historical success. Posts on X also touch on the company’s strategic focus on life sciences and diagnostics, with a few expressing optimism about future growth despite current market softness. This blend of technical and fundamental perspectives keeps the dialogue engaging and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Danaher Corporation Congressional Stock Trading
Members of Congress have traded $DHR stock 8 times in the past 6 months. Of those trades, 3 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:
- REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/03, 06/11 and 0 sales.
- SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 08/28.
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 07/22.
- REPRESENTATIVE PETE SESSIONS sold up to $100,000 on 06/12.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 05/15.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Danaher Corporation Insider Trading Activity
Danaher Corporation insiders have traded $DHR stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:
- STEVEN M RALES (Chairman) has made 0 purchases and 8 sales selling 1,250,000 shares for an estimated $245,919,390.
- CHRISTOPHER PAUL RILEY (Executive Vice President) has made 0 purchases and 2 sales selling 15,805 shares for an estimated $3,129,424.
- TERI LIST sold 2,778 shares for an estimated $586,319
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Danaher Corporation Hedge Fund Activity
We have seen 953 institutional investors add shares of Danaher Corporation stock to their portfolio, and 1,054 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,976,077 shares (-15.2%) from their portfolio in Q2 2025, for an estimated $587,894,250
- EAGLE CAPITAL MANAGEMENT LLC added 2,859,518 shares (+inf%) to their portfolio in Q2 2025, for an estimated $564,869,185
- MARSHALL WACE, LLP removed 2,761,062 shares (-76.6%) from their portfolio in Q2 2025, for an estimated $545,420,187
- CITADEL ADVISORS LLC removed 2,549,058 shares (-96.7%) from their portfolio in Q2 2025, for an estimated $503,540,917
- PARNASSUS INVESTMENTS, LLC added 2,489,510 shares (+65.0%) to their portfolio in Q2 2025, for an estimated $491,777,805
- VIKING GLOBAL INVESTORS LP added 2,455,994 shares (+543.9%) to their portfolio in Q2 2025, for an estimated $485,157,054
- GENERATION INVESTMENT MANAGEMENT LLP added 1,787,522 shares (+56.2%) to their portfolio in Q2 2025, for an estimated $353,107,095
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Danaher Corporation Government Contracts
We have seen $110,387,543 of award payments to $DHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- MOLECULAR DIAGNOSTIC TESTS FOR SARS-COV-2: $3,970,565
- POLYMERASE CHAIN REACTION (PCR) DIAGNOSTIC TESTING FOR VISN 2 DOWNSTATE: $3,781,390
- AB SCIEX SERVICE & MAINTENANCE AGREEMENT SUPPORT: $3,403,150
- IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD ONE: $2,898,933
- IN-VITRO REAGENTS: $2,304,881
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Danaher Corporation Analyst Ratings
Wall Street analysts have issued reports on $DHR in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- B of A Securities issued a "Buy" rating on 09/22/2025
- Baird issued a "Outperform" rating on 07/23/2025
- Guggenheim issued a "Buy" rating on 07/23/2025
- UBS issued a "Buy" rating on 07/23/2025
- Scotiabank issued a "Sector Outperform" rating on 07/11/2025
- Barclays issued a "Overweight" rating on 06/24/2025
To track analyst ratings and price targets for Danaher Corporation, check out Quiver Quantitative's $DHR forecast page.
Danaher Corporation Price Targets
Multiple analysts have issued price targets for $DHR recently. We have seen 13 analysts offer price targets for $DHR in the last 6 months, with a median target of $230.0.
Here are some recent targets:
- Ed Ridley-Day from Rothschild & Co set a target price of $220.0 on 10/08/2025
- Vijay Kumar from Evercore ISI Group set a target price of $245.0 on 10/07/2025
- Derik De Bruin from B of A Securities set a target price of $220.0 on 09/22/2025
- Dan Leonard from UBS set a target price of $225.0 on 07/23/2025
- Brandon Couillard from Wells Fargo set a target price of $205.0 on 07/23/2025
- Subbu Nambi from Guggenheim set a target price of $250.0 on 07/23/2025
- Catherine Schulte from Baird set a target price of $229.0 on 07/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
